Skip to main content

Advertisement

Log in

Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background and aim

Although miR-203 has been proposed as a relevant biomarker for several cancers, the validated prognostic significance of miR-203 in lung cancer remains obscure. Thus, we aimed to identify the relationship between miR-203 expression and clinicopathological significance in non-small cell lung cancer (NSCLC) patients in the current study.

Methods

The expression of miR-203 in 125 cases of NSCLC and their paired adjacent non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Simultaneously, the correlation of miR-203 expression with a variety of clinicopathological factors and patient survival was analyzed. Functionally, in vitro effects of miR-203 on proliferation and viability were explored in lung cancer H460, A549, H1299, PC9 and H292 cells, as assessed by MTS tetrazolium assay and fluorimetric resorufin viability assay, respectively.

Results

The relative level of miR-203 was 6.12 ± 6.25 in NSCLC tissues, remarkably downregulated than that of their paired non-tumorous lung tissues (7.88 ± 5.56, P = 0.019). The area under curve (AUC) of low expression of miR-203 to diagnose NSCLC was 0.622 (95 % CI 0.552–0.692, P = 0.001). MiR-203 expression was negatively correlated to lymphatic metastasis (r = −0.334, P < 0.001), tumor size (r = −0.407, P < 0.001) and clinical TNM stages (r = −0.298, P = 0.001). Furthermore, the survival of the low miR-203 expression group was 4.88 ± 4.38 months, markedly shorter than that of the high expression group (23.35 ± 1.12 months, P < 0.001). The level of miR-203 was an independent prognostic indicator of NSCLC using univariate analysis. MiR-203 mimic could suppress the cell growth of five lung cancer cell lines tested to different degrees in vitro.

Conclusions

MiR-203 could become a prognostic predictor in NSCLC and may be a new target for the molecular therapy of NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Lee PN, Forey BA. Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review. BMC Cancer. 2013;13:189.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chen X, Liu Y, Roe OD, Qian Y, Guo R, Zhu L, et al. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One. 2013;8(3):e59314.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A. Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med. 2013;11:168.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochem Biophys Res Commun. 2014;455(1–2):70–83.

    Article  CAS  PubMed  Google Scholar 

  5. Gazala S, Pelletier JS, Storie D, Johnson JA, Kutsogiannis DJ, Bedard EL. A systematic review and meta-analysis to assess patient-reported outcomes after lung cancer surgery. Sci World J. 2013;2013:789625.

    Article  Google Scholar 

  6. Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, et al. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Oncol Res. 2013;21(3):137–44.

    Article  PubMed  Google Scholar 

  7. Roy M, Luo YH, Ye M, Liu J. Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int. 2013;2013:964743.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Di Leva G, Briskin D, Croce CM. MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Upsala J Med Sci. 2012;117(2):202–16.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ramshankar V, Krishnamurthy A. Lung cancer detection by screening—presenting circulating miRNAs as a promising next generation biomarker breakthrough. Asian Pac J Cancer Prev APJCP. 2013;14(4):2167–72.

    Article  PubMed  Google Scholar 

  10. Verderio P, Bottelli S, Ciniselli CM, Pierotti MA, Gariboldi M, Pizzamiglio S. NqA: an R-based algorithm for the normalization and analysis of microRNA quantitative real-time polymerase chain reaction data. Anal Biochem. 2014;461:7–9.

    Article  CAS  PubMed  Google Scholar 

  11. Ritchie W, Rasko JE. Refining microRNA target predictions: sorting the wheat from the chaff. Biochem Biophys Res Commun. 2014;445(4):780–4.

    Article  CAS  PubMed  Google Scholar 

  12. Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer. 2011;11:500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chen Z, Xu L, Ye X, Shen S, Li Z, Niu X, et al. Polymorphisms of microRNA sequences or binding sites and lung cancer: a meta-analysis and systematic review. PLoS One. 2013;8(4):e61008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Oom AL, Humphries BA, Yang C. MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int. 2014;2014:959461.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. 2013;19(7):1292–300.

    CAS  PubMed  Google Scholar 

  16. Tian L, Li M, Ge J, Guo Y, Sun Y, Liu M, et al. MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol J Int Soc for Oncodev Biol Med. 2014;35(6):5953–63.

    Article  CAS  Google Scholar 

  17. Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(4):981–92.

    Article  Google Scholar 

  18. Gocze K, Gombos K, Juhasz K, Kovacs K, Kajtar B, Benczik M, et al. Unique microRNA expression profiles in cervical cancer. Anticancer Res. 2013;33(6):2561–7.

    CAS  PubMed  Google Scholar 

  19. Sonkoly E, Loven J, Xu N, Meisgen F, Wei T, Brodin P, et al. MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma. Oncogenesis. 2012;1:e3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, et al. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget. 2014;5(11):3770–84.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Chen G, Kronenberger P, Teugels E, De Greve J. Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol Proced Online. 2011;13:1.

    Article  CAS  PubMed Central  Google Scholar 

  22. Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J. Effect of siRNAs targeting the EGFR T790 M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun. 2013;431(3):623–9.

    Article  CAS  PubMed  Google Scholar 

  24. Chen G, Kronenberger P, Umelo IA, Teugels E, De Greve J. Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem. 2010;398(2):266–8.

    Article  CAS  PubMed  Google Scholar 

  25. Chen G, Noor A, Kronenberger P, Teugels E, Umelo IA, De Greve J. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 2013;8(3):e59708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, et al. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One. 2013;8(3):e60317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Rong M, He R, Dang Y, Chen G. Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Upsala J Med Sci. 2014;119(1):19–24.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Albertini MC, Olivieri F, Lazzarini R, Pilolli F, Galli F, Spada G, et al. Predicting microRNA modulation in human prostate cancer using a simple String IDentifier (SID1.0). J Biomed Inform. 2011;44(4):615–20.

    Article  CAS  PubMed  Google Scholar 

  29. Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One. 2013;8(4):e61054.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Dang YW, Zeng J, He RQ, Rong MH, Luo DZ, Chen G. Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev APJCP. 2014;15(12):4969–76.

    Article  PubMed  Google Scholar 

  31. Jin J, Deng J, Wang F, Xia X, Qiu T, Lu W, et al. The expression and function of microRNA-203 in lung cancer. Tumour Biol J Int Soc for Oncodev Biol Med. 2013;34(1):349–57.

    Article  CAS  Google Scholar 

  32. Wang C, Wang X, Liang H, Wang T, Yan X, Cao M, et al. miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCalpha. PLoS One. 2013;8(9):e73985.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang N, Liang H, Zhou Y, Wang C, Zhang S, Pan Y, et al. miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC. PLoS One. 2014;9(8):e105570.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Benaich N, Woodhouse S, Goldie SJ, Mishra A, Quist SR, Watt FM. Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis. Cell Rep. 2014;9(1):104–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wairagu PM, Park KH, Kim J, Choi JW, Kim HW, Yeh BI, et al. Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer. Biochem Biophys Res Commun. 2014;447(3):490–5.

    Article  CAS  PubMed  Google Scholar 

  36. Soma S, Tsuta K, Takano T, Hatanaka Y, Yoshida A, Suzuki K, et al. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma. Pathol Res Pract. 2014;210(3):155–60.

    Article  CAS  PubMed  Google Scholar 

  37. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2012;18(1):74–82.

    CAS  PubMed Central  Google Scholar 

Download references

Acknowledgments

The study was supported by the Fund of Guangxi Provincial Health Bureau Scientific Research Project (Z2013201, Z2014055) and the Fund of National Natural Science Foundation of China (NSFC 81360327). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Ruixue Tang and Tengfei Zhong contributed equally to this paper.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to P. Li or G. Chen.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Additional information

R. Tang and T. Zhong contributed equally.

P. Li and G. Chen contributed equally.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, R., Zhong, T., Dang, Y. et al. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients. Clin Transl Oncol 18, 360–368 (2016). https://doi.org/10.1007/s12094-015-1377-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1377-9

Keywords

Navigation